A Structure Therapeutics obesity pill helped patients lose an average of nearly 40 pounds in a mid-stage clinical trial, keeping the drug competitive in the growing crowd of oral medications pursuing ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

There has been a wealth of titans on Monarch: Legacy of Monsters Season 2 so far, but the mysterious sea creature that has a small village in a chokehold is quickly becoming one of my favorites.

Deep inside Earth, two massive hot rock structures have been quietly shaping the planet’s magnetic field for millions of years. Using ancient magnetic records and advanced simulations, scientists ...

At a White House meeting called to thaw the ice between crypto firms and Wall Street bankers, the eager crypto insiders — who outnumbered the bankers by a wide margin — came away feeling the banks ...

JEE Main Answer Key 2026: The JEE Main 2026 January Session has concluded successfully. The National Testing Agency (NTA conducted the examination over multiple days and shifts in computer-based test ...

Abstract: In this article, a lossy coplanar electromagnetic bandgap (EBG) structure embedded with periodic resistors is proposed for anti-resonance suppression and stopband extension. With the aid of ...

Blue Protocol: Star Resonance has an overview of Season 2, Dreambloom - Echoes of Lost Nightmares, which launches this week. The new season begins January 15th, and the content in the seasonal update ...

Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line treatment ...